ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline
- Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF)
- Proceeds will accelerate the expansion of ALLOX’s high-throughput biophysics and AI drug discovery platform and the advancement of a focused pipeline of small molecules against high-value, historically difficult-to-drug protein-protein interactions and transcription factors
- Seasoned biotech executive and investor Morten Graugaard, Co-founder and CBO of Orbis Medicines, appointed Independent Chair of the Board
Barcelona, Spain, 29 October 2026 – ALLOX, a biotechnology company developing a high-throughput, experimental-first platform to discover and exploit allosteric sites and other regulatory regions for drug discovery, today announced the successful closing of its US$10.5m (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors. The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF).
